Clinical Efficacy of Crizotinib as the First-Line Therapy of Advanced Non-Small-Cell Lung Carcinoma with ROS-1 Rearrangement: A Systematic Review
Background: Crizotinib is a drug designed to treat advanced NSCLC with ROS-1 rearrangement. Nevertheless, no reviews have assessed available studies to determine the efficacy and safety of first-line crizotinib against advanced NSCLC with ROS-1 rearrangement. Methods: PubMed, Cochrane Library, EB...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dharmais Cancer Hospital - National Cancer Center
2023-06-01
|
| Серии: | Indonesian Journal of Cancer |
| Предметы: | |
| Online-ссылка: | https://www.indonesianjournalofcancer.or.id/e-journal/index.php/ijoc/article/view/933 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|